Primetime entered into a CRADA with NIH/NCATS to develop antimicrobial agents for antimicrobial resistant infections
GERMANTOWN, MD, UNITED STATES, August 3, 2018 /EINPresswire.com/ -- Primetime Life Sciences, LLC has signed a Collaborative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health (NIH). Working together, Primetime and NCATS will identify, optimize, and develop novel inhibitors of chorismate mutase for the treatment of antimicrobial resistant infections. Under the terms of the agreement, Primetime will collaborate with Dr. James Inglese, who directs the assay development and screening technology laboratory within the NCATS Division of Pre-Clinical Innovation. The scope of the CRADA research plan includes quantitative high throughput screening (qHTS) for the measurement of chorismate mutase (CM) enzymatic activity and lead optimization of the validated hits to identify a preclinical candidate.
The collaboration integrates the capability and expertise Dr. Inglese’s lab at NCATS with the medicinal chemistry and drug development expertise at Primetime to identify a potent and selective inhibitor of chorismate mutase for treatment of microbial infections, particularly Mycobacterium tuberculosis.
“We are delighted to be working with Dr. Inglese and his group at NCATS,” commented Dr. Janak Padia, President, and CEO of Primetime. “The collaboration will bring substantial expertise and resources to discover and develop new chorismate mutase inhibitors for safe and effective treatment for the microbial disease. There is an unmet need for treatment for resistant Mycobacterium tuberculosis, and Primetime is proud to work alongside of NCATS in this endeavor”
Dr. Inglese noted, “We look forward to collaborating with Dr. Padia to discover novel inhibitors for one of nature’s most fascinating catalysts.”
NOTES TO EDITORS
About chorismate mutase:
Chorismate mutase catalyzes the Claisen rearrangement of chorismate to prephenate in the shikimate pathway which leads to the synthesis of the aromatic amino acids phenylalanine and tyrosine. This is the single known example of an enzyme catalyzing a pericyclic reaction. The shikimate pathway for the biosynthesis of aromatic compounds is evidently present in bacteria, fungi, and plants but absent in humans and therefore, chorismate mutase is a valid target for generation of antimicrobial agents and particularly important for drug-resistant bacterial and fungal infections.
About Primetime:
Primetime Life Sciences, LLC (www.primetimelifesci.com) is an early-stage pharmaceutical company based in Maryland, developing small molecule drugs. Primetime’s mission is to expedite the discovery and development of new and smart treatments by using a multi-
disciplinary, highly collaborative, "bench-to-bedside" approach. Primetime’s translational medicine approach is focused on ensuring proven strategies for disease treatment and prevention.
Primetime has developed preparatory mutual prodrug platform technology (Metual®) to discover and develop small molecule drugs that exert therapeutic effects through synergistic mechanisms with improved drug attributes.
For more information please contact Dr. Janak Padia, jpadia@primetimelifesci.com. http://www.primetimelifesci.com
The collaboration integrates the capability and expertise Dr. Inglese’s lab at NCATS with the medicinal chemistry and drug development expertise at Primetime to identify a potent and selective inhibitor of chorismate mutase for treatment of microbial infections, particularly Mycobacterium tuberculosis.
“We are delighted to be working with Dr. Inglese and his group at NCATS,” commented Dr. Janak Padia, President, and CEO of Primetime. “The collaboration will bring substantial expertise and resources to discover and develop new chorismate mutase inhibitors for safe and effective treatment for the microbial disease. There is an unmet need for treatment for resistant Mycobacterium tuberculosis, and Primetime is proud to work alongside of NCATS in this endeavor”
Dr. Inglese noted, “We look forward to collaborating with Dr. Padia to discover novel inhibitors for one of nature’s most fascinating catalysts.”
NOTES TO EDITORS
About chorismate mutase:
Chorismate mutase catalyzes the Claisen rearrangement of chorismate to prephenate in the shikimate pathway which leads to the synthesis of the aromatic amino acids phenylalanine and tyrosine. This is the single known example of an enzyme catalyzing a pericyclic reaction. The shikimate pathway for the biosynthesis of aromatic compounds is evidently present in bacteria, fungi, and plants but absent in humans and therefore, chorismate mutase is a valid target for generation of antimicrobial agents and particularly important for drug-resistant bacterial and fungal infections.
About Primetime:
Primetime Life Sciences, LLC (www.primetimelifesci.com) is an early-stage pharmaceutical company based in Maryland, developing small molecule drugs. Primetime’s mission is to expedite the discovery and development of new and smart treatments by using a multi-
disciplinary, highly collaborative, "bench-to-bedside" approach. Primetime’s translational medicine approach is focused on ensuring proven strategies for disease treatment and prevention.
Primetime has developed preparatory mutual prodrug platform technology (Metual®) to discover and develop small molecule drugs that exert therapeutic effects through synergistic mechanisms with improved drug attributes.
For more information please contact Dr. Janak Padia, jpadia@primetimelifesci.com. http://www.primetimelifesci.com
Janak Padia, PhD
Primetime Life Sciences, LLC
2407155906
email us here